A -- PHASE II CLINICAL STUDIES OF NEW CHEMOPREVENTIVE AGENTS

Notice Date

December 14, 2001

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852

ZIP Code

20852

Solicitation Number

N01-CN-25011-46

Response Due

March 15, 2002

Point of Contact

Schuyler Eldridge, Contracting Officer, Phone (301) 435-3794, Fax (301) 402-8579, Email se29f@nih.gov

Description

ELECTRONIC RFP ANNOUNCEMENT: POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS.) The Division of Cancer Prevention (DCP), National Cancer Institute (NCI), National Institute of Health (NIH), intends to award up to three contracts under the existing Master Agreement (MA) pool for "Phase II Clinical Trials of New Chemopreventive Agents". The RFP consists of three workstatements (Nos. 79 through 81) as follows: No 79 A Phase IIb Cancer Prevention Trial of NSAIDs in Oral Leukoplakia; No. 80 An Exploratory Study to Evaluate the Effect of HPV 16 Vaccine on the Reduction of Viral Load in HPV 16 Positive Women with Persistent Viral Infection, but Low Grade Disease (ASCUS/LSIL); No. 81 Phase IIb Randomized, Placebo-Controlled Trial of an NSAID for the Modulation of Biomarkers in Monoclonal Gammopathy of Undetermined Significance (MGUS); The North American Industry Classification System (NAICS) for this project is 541710. AN AWARD WILL ONLY BE MADE TO A MASTER AGREEMENT HOLDER IN THE PHASE II CLINICAL TRIALS OF NEW CHEMOPREVENTIVE AGENTS MASTER AGREEMENT POOL. Those who are not currently in the Phase II Clinical Trials of New Chemopreventive Agents Master Agreement Pool and who wish to be considered for inclusion should consult the NCI Research Contracts Branch website at http://rcb.nci.nih.gov/ under ?Current Request for Proposals? scroll to Master Agreement Announcements and refer to RFP No. N01-CN-85077-57. The duration of the current Phase II Master Agreement Pool is 10/1997 through 10/2002. Please see the Master Agreement Announcement for due dates of proposals and further instructions on how to become a member of the Phase II Clinical Trials of New Chemoprevention Agents Master Agreement Pool. It is anticipated that this RFP No. N01-CN-25011-46 will be available after January 4, 2002. It is the offeror?s responsibility to request a copy of the RFP. Point of contact: Schuyler T. Eldridge, Contracting Officer, NCI, RCB, PCPSS; 6120 Executive Boulevard, Executive Plaza South, Room 635, Rockville, MD 20852; Email address: se29f@nih.gov; Telephone: (301) 435-3794; Fax (301) 402-8579. All requests should reference the RFP No. N01-CN-25011-46. No collect calls will be accepted. Numbered Note 26 -- Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

Web Link

Visit this URL for the latest information about this (http://www.eps.gov/spg/HHS/NIH/RCB/N01-CN-25011-46/listing.html)

Record

Loren Data Corp. 20011218/ASOL009.HTM (D-348 SN5152G9)